JPWO2020227101A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227101A5 JPWO2020227101A5 JP2021564995A JP2021564995A JPWO2020227101A5 JP WO2020227101 A5 JPWO2020227101 A5 JP WO2020227101A5 JP 2021564995 A JP2021564995 A JP 2021564995A JP 2021564995 A JP2021564995 A JP 2021564995A JP WO2020227101 A5 JPWO2020227101 A5 JP WO2020227101A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- phenyl
- group
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 336
- 150000001875 compounds Chemical class 0.000 claims description 231
- 125000003545 alkoxy group Chemical group 0.000 claims description 145
- 229910052736 halogen Inorganic materials 0.000 claims description 134
- 150000002367 halogens Chemical class 0.000 claims description 126
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 124
- 125000001072 heteroaryl group Chemical group 0.000 claims description 120
- 229910052739 hydrogen Inorganic materials 0.000 claims description 119
- 239000001257 hydrogen Substances 0.000 claims description 119
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 98
- 150000003839 salts Chemical class 0.000 claims description 90
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 82
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 76
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 73
- 125000001424 substituent group Chemical group 0.000 claims description 63
- 239000008194 pharmaceutical composition Substances 0.000 claims description 52
- 150000002431 hydrogen Chemical class 0.000 claims description 45
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 35
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 33
- 208000012902 Nervous system disease Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 230000035772 mutation Effects 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 21
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 20
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 claims description 18
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 claims description 18
- 208000014644 Brain disease Diseases 0.000 claims description 17
- 208000032274 Encephalopathy Diseases 0.000 claims description 17
- 206010015037 epilepsy Diseases 0.000 claims description 17
- 208000025966 Neurological disease Diseases 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 206010001497 Agitation Diseases 0.000 claims description 13
- 230000001037 epileptic effect Effects 0.000 claims description 12
- 230000001537 neural effect Effects 0.000 claims description 12
- 206010061334 Partial seizures Diseases 0.000 claims description 11
- 206010010904 Convulsion Diseases 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 7
- 208000023944 Sudden Unexpected Death in Epilepsy Diseases 0.000 claims description 7
- 201000007186 focal epilepsy Diseases 0.000 claims description 7
- -1 substituted Chemical class 0.000 claims description 7
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 4
- 201000007547 Dravet syndrome Diseases 0.000 claims description 4
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims description 4
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims description 4
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 claims description 4
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims description 4
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 4
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims description 4
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims description 4
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 claims description 4
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims description 4
- 230000001617 migratory effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000008587 neuronal excitability Effects 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 claims description 2
- 208000020749 Benign familial neonatal-infantile seizures Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010059027 Brugada syndrome Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 2
- 208000024658 Epilepsy syndrome Diseases 0.000 claims description 2
- 208000002877 Epileptic Syndromes Diseases 0.000 claims description 2
- 208000002091 Febrile Seizures Diseases 0.000 claims description 2
- 208000003078 Generalized Epilepsy Diseases 0.000 claims description 2
- 206010021750 Infantile Spasms Diseases 0.000 claims description 2
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims description 2
- 201000006347 Intellectual Disability Diseases 0.000 claims description 2
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 claims description 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims description 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims description 2
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000029578 Muscle disease Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 206010061533 Myotonia Diseases 0.000 claims description 2
- 208000037158 Partial Epilepsies Diseases 0.000 claims description 2
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims description 2
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 206010043994 Tonic convulsion Diseases 0.000 claims description 2
- 201000006791 West syndrome Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 208000032212 benign familial infantile 3 seizures Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000017888 childhood-onset epilepsy syndrome Diseases 0.000 claims description 2
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 claims description 2
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- 208000036546 leukodystrophy Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 208000000209 Isaacs syndrome Diseases 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 241000149788 Pseudophryne major Species 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 206010029323 Neuromyopathy Diseases 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025062493A JP2025102975A (ja) | 2019-05-03 | 2025-04-04 | Ｋｃｎｔ１阻害剤および使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842849P | 2019-05-03 | 2019-05-03 | |
| US62/842,849 | 2019-05-03 | ||
| US202062982864P | 2020-02-28 | 2020-02-28 | |
| US62/982,864 | 2020-02-28 | ||
| PCT/US2020/031046 WO2020227101A1 (en) | 2019-05-03 | 2020-05-01 | Kcnt1 inhibitors and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062493A Division JP2025102975A (ja) | 2019-05-03 | 2025-04-04 | Ｋｃｎｔ１阻害剤および使用する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022531388A JP2022531388A (ja) | 2022-07-06 |
| JPWO2020227101A5 true JPWO2020227101A5 (https=) | 2023-05-11 |
| JP2022531388A5 JP2022531388A5 (https=) | 2023-05-11 |
| JP7667573B2 JP7667573B2 (ja) | 2025-04-23 |
Family
ID=73051241
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564995A Active JP7667573B2 (ja) | 2019-05-03 | 2020-05-01 | Ｋｃｎｔ１阻害剤および使用する方法 |
| JP2025062493A Pending JP2025102975A (ja) | 2019-05-03 | 2025-04-04 | Ｋｃｎｔ１阻害剤および使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062493A Pending JP2025102975A (ja) | 2019-05-03 | 2025-04-04 | Ｋｃｎｔ１阻害剤および使用する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220259193A1 (https=) |
| EP (1) | EP3962481A4 (https=) |
| JP (2) | JP7667573B2 (https=) |
| KR (1) | KR20220016086A (https=) |
| CN (2) | CN114269340A (https=) |
| AU (1) | AU2020267356B2 (https=) |
| BR (1) | BR112021022067A2 (https=) |
| CA (1) | CA3139063A1 (https=) |
| CL (2) | CL2021002877A1 (https=) |
| CO (1) | CO2021016471A2 (https=) |
| EC (1) | ECSP21087884A (https=) |
| IL (1) | IL287768A (https=) |
| MX (1) | MX2021013421A (https=) |
| PE (1) | PE20220016A1 (https=) |
| SA (1) | SA521430751B1 (https=) |
| SG (1) | SG11202112158YA (https=) |
| WO (1) | WO2020227101A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12590083B2 (en) | 2019-01-25 | 2026-03-31 | University Of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy |
| KR20250172745A (ko) * | 2019-05-03 | 2025-12-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| JP7699836B2 (ja) * | 2020-02-28 | 2025-06-30 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤、および使用方法 |
| EP4210824A1 (en) * | 2020-09-09 | 2023-07-19 | University of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (spns2) for use in therapy |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| TW202227424A (zh) * | 2020-11-27 | 2022-07-16 | 大陸商瑞石生物醫藥有限公司 | 芳基或雜芳基取代５員芳雜環化合物及其用途 |
| WO2022140547A2 (en) * | 2020-12-22 | 2022-06-30 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| WO2022231872A1 (en) * | 2021-04-29 | 2022-11-03 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| EP4329735B1 (en) * | 2021-04-29 | 2026-02-25 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| WO2023211850A1 (en) * | 2022-04-25 | 2023-11-02 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use |
| US20250360117A1 (en) * | 2022-06-08 | 2025-11-27 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use |
| CN116813505B (zh) * | 2023-06-29 | 2025-09-02 | 爱斯特（成都）生物制药股份有限公司 | 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法 |
| WO2025117662A1 (en) * | 2023-11-29 | 2025-06-05 | Actio Biosciences, Inc. | Heterocyclic compounds useful as kcnt1 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| TW200301698A (en) * | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| JP2005060255A (ja) * | 2003-08-20 | 2005-03-10 | Nippon Nohyaku Co Ltd | カルボキサミド類及びこれを有効成分とする有害生物防除剤 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP2044061A2 (en) * | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| ES2895174T3 (es) | 2014-09-29 | 2022-02-17 | Scripps Research Inst | Moduladores del receptor de esfingosina-1-fosfato para el tratamiento de trastornos cardiopulmonares |
| EP3275440B1 (en) * | 2015-03-25 | 2022-05-04 | National Center for Geriatrics and Gerontology | Novel oxadiazole derivative and pharmaceutical containing same |
| JPWO2017170826A1 (ja) * | 2016-03-30 | 2019-02-14 | 味の素株式会社 | グルカゴン様ペプチド−１受容体作用増強活性を有する化合物 |
| WO2018187480A1 (en) * | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JP7699836B2 (ja) * | 2020-02-28 | 2025-06-30 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤、および使用方法 |
| KR20230005168A (ko) * | 2020-03-23 | 2023-01-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| CA3188825A1 (en) * | 2020-07-06 | 2022-01-13 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| US11773088B2 (en) * | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| WO2022140547A2 (en) * | 2020-12-22 | 2022-06-30 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| EP4329735B1 (en) * | 2021-04-29 | 2026-02-25 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
-
2020
- 2020-05-01 KR KR1020217039174A patent/KR20220016086A/ko not_active Ceased
- 2020-05-01 BR BR112021022067A patent/BR112021022067A2/pt unknown
- 2020-05-01 AU AU2020267356A patent/AU2020267356B2/en active Active
- 2020-05-01 SG SG11202112158YA patent/SG11202112158YA/en unknown
- 2020-05-01 WO PCT/US2020/031046 patent/WO2020227101A1/en not_active Ceased
- 2020-05-01 CN CN202080047961.1A patent/CN114269340A/zh active Pending
- 2020-05-01 MX MX2021013421A patent/MX2021013421A/es unknown
- 2020-05-01 CA CA3139063A patent/CA3139063A1/en active Pending
- 2020-05-01 US US17/607,802 patent/US20220259193A1/en active Pending
- 2020-05-01 PE PE2021001828A patent/PE20220016A1/es unknown
- 2020-05-01 CN CN202510784123.7A patent/CN120817941A/zh active Pending
- 2020-05-01 EP EP20801870.5A patent/EP3962481A4/en active Pending
- 2020-05-01 JP JP2021564995A patent/JP7667573B2/ja active Active
-
2021
- 2021-11-01 IL IL287768A patent/IL287768A/en unknown
- 2021-11-02 CL CL2021002877A patent/CL2021002877A1/es unknown
- 2021-11-03 SA SA521430751A patent/SA521430751B1/ar unknown
- 2021-12-02 CO CONC2021/0016471A patent/CO2021016471A2/es unknown
- 2021-12-03 EC ECSENADI202187884A patent/ECSP21087884A/es unknown
-
2024
- 2024-07-08 CL CL2024002067A patent/CL2024002067A1/es unknown
-
2025
- 2025-04-04 JP JP2025062493A patent/JP2025102975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020227101A5 (https=) | ||
| JP2021525800A5 (https=) | ||
| JP2023144130A5 (https=) | ||
| JP2007516983A5 (https=) | ||
| JP2015522036A5 (https=) | ||
| JP2010513519A5 (https=) | ||
| JP2011500815A5 (https=) | ||
| RU2460730C2 (ru) | Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли | |
| CN112638877B (zh) | 用于治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物 | |
| JP2004529140A5 (https=) | ||
| JP2007501831A5 (https=) | ||
| JP2006506462A5 (https=) | ||
| JP2005514398A5 (https=) | ||
| RU2010114828A (ru) | Производные урацила или тимина для лечения гепатита с | |
| Highfill et al. | Superstructural variety from an alkylated triazine: Formation of one-dimensional hydrogen-bonded arrays or cyclic rosettes | |
| JP2010501003A5 (https=) | ||
| WO1997037989A1 (en) | Indole derivatives as 5-ht receptor antagonist | |
| CA2525841A1 (en) | Cyclohexyl sulphones as gamma-secretase inhibitors | |
| JP2017537949A5 (https=) | ||
| JP2004534096A5 (https=) | ||
| EP3994216A1 (en) | Antimicrobial dyes for facemasks | |
| AU2015338946A1 (en) | Potent gamma-secretase modulators | |
| JP2021521178A5 (https=) | ||
| RU2015116532A (ru) | Ингибиторы тирозинкиназы syk | |
| Makki et al. | New route to synthesize fluorine substituted lamotrigine drug analogues as an anti-inflammatory agent |